$VIR News

Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This Quarter

Is Vir Biotechnology (VIR) Undervalued On Its Gilead Oncology Deal?

Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results

What Does Gilead Sciences (GILD) Gain From Its New Solid Tumor Partnership?

Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors

Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties

Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

Vir Biotechnology Receives FDA Fast Track Designation For VIR-5500 To Treat Metastatic Castration-Resistant Prostate Cancer

How Upcoming SOLSTICE Phase 2 HDV Data Could Shape Vir Biotechnology’s (VIR) Investment Narrative

Vir Biotechnology Appoints David Liu as Chief Medical Officer

HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026

Vir Biotechnology To Reveal Expanded Phase 2 SOLSTICE Results for Elebsiran And Tobevibart In Hepatitis Delta at AASLD’s The Liver Meeting 2026

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

Vir Biotechnology Appoints Aziz Sawaf CFO, Effective Oct. 5

Vir Biotechnology: Astellas Deal Highlights The Platform's Value

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference